On the evening of July 17, Tiantan BiotechnologyDisclose announcements on the progress of clinical trials of drugs of affiliated companies.

The announcement shows that the company's subsidiary Chengdu Rongsheng Pharmaceutical Co., Ltd.'s marketed product "Intravenous Human Immunoglobulin (pH4)" (10%, 50ml) has completed clinical ethics review, pre-clinical preparations and other work for the new indication of chronic inflammatory demyelinating polyradiculoneuropathy, and has officially started Phase III clinical trials recently.

This newly added indication is the first intravenous human immunoglobulin product in China to be approved for clinical research on the indication of chronic inflammatory demyelinating polyradiculoneuropathy. The main procedures that need to be fulfilled for the above-mentioned product to be approved for the new indication include: completing Phase III clinical trials, submitting an application for a license for the new indication, and obtaining approval for the new indication after passing the review of the Drug Evaluation Center of the National Medical Products Administration and the approval of the National Medical Products Administration.

https://finance.eastmoney.com/a/202507183460530822.html